Latest Tax Rebates News

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Wide Open Agriculture Ltd (ASX: WOA) has received a A$1,686,579 R&D tax rebate for the 2024-25 financial year, reflecting its significant innovation efforts in lupin protein development across Australia and Germany. The rebate will support the company’s commercialisation and growth initiatives.

PlaySide Studios Limited (ASX: PLY) has announced that its upcoming game MOUSE: P.I. For Hire has exceeded 1.5 million wishlists, surpassing previous guidance, ahead of its global digital launch on 16 April 2026. The company expects FY26 revenue to exceed FY25 with reduced operating costs.

Sparc Technologies has secured a $680,000 non-dilutive advance on its anticipated FY26 R&D tax refund, strengthening its cash flow as it accelerates commercialisation of its graphene additive ecosparc and green hydrogen ventures.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

New Frontier Minerals has secured technical approval for its Mining Lease Application at the Big One Copper Deposit, setting the stage for potential near-term copper production amid a tightening global copper market.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

South Harz Potash Limited has raised A$1.25 million to fund exploration at its newly licensed copper-gold projects in Sweden, signalling a strategic pivot towards critical minerals and a planned rebrand to Turnstone Resources.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.